AI

Aethlon Medical, Inc.

Request removal

Aethlon is focused on addressing unmet needs in global health. The Aethlon Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. In cancer, the Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression. The Hemopurifier® is an FDA designated "Breakthrough Device" related to the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. Under an Investigational Device Exemption (IDE) application, in October 2019, the FDA approved an Early Feasibility Study (EFS), which is the device equivalent of a Phase 1 clinical trial for a drug or biologic, in a single center, open label trial in 10 to 12 subjects. The study is evaluating the HEMOPURIFIER® for reducing cancer-associated exosomes prior to the administration of standard-of-care pembrolizumab (KEYTRUDA®), which is a first-line therapy for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. The EFS is being conducted at the University of Pittsburgh Medical Center Hillman Cancer Center. The Hemopurifier also holds a Breakthrough Device designation related to life-threatening viruses that are not addressed with approved therapies. In June 2020, the FDA approved an amendment to the Company's existing open IDE for the Hemopurifier in life threatening viral infections, to allow for the treatment of patients with SARS-CoV-2/COVID-19 infection. This will allow for up to 40 of these patients to be treated under a new Early Feasibility Study protocol at up to 20 clinical sites in the U.S. Aethlon also owns 80% of Exosome Sciences, Inc., which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease progression.

Get valid emails for people working at Aethlon Medical, Inc. and 200M other companies
20 free emails each month. No credit card required.
500M
Business Profiles
20M
Company Profiles
200M
Email addresses
98%+
Email Delivery
Aethlon Medical, Inc.'s headquarter address
Line 1: 9635 granite ridge drive, san diego, california, usa, 92123
Line 2: 9635 Granite Ridge Dr
Aethlon Medical, Inc.'s industries
medical devices
Aethlon Medical, Inc.'s technology
Amazon AWS Apache Google Analytics Google Font API Microsoft Office 365 Mobile Friendly Outlook Route 53 reCAPTCHA
Find emails from LinkedIn for free
20 free emails each month. No credit card required.
Regular search results
Search for leads on linkedin.com and scrape the search results
Sales Navigator search results
Search for leads in LinkedIn sales navigator and scrape the search results
Group members
Scrape members from any LinkedIn group without joining it
Event attendees
Scrape event attendees from any LinkedIn event
Directory